Mid-term outcomes of aortic valve replacement using the freedom solo® stentless bioprosthesis at Bach Mai Hospital

Objectives: To evaluate mid-term outcomes of aortic valve replacement using the Freedom Solo® stentless bioprosthesis (Sorin Biomedica Group) at Bach Mai hospital, Hanoi. Subjects and methods: This prospective and descriptive study was carried out in patients undergoing aortic valve replacement using Freedom Solo® stentless bioprosthesis (Sorin Biomedica Group) at Bach Mai Hospital from 01/2016 to 5/2022. Results: 53 patients aged 62.8 ± 6.1 years old were enrolled in the study. Male patients were 67.9%. The predicted mortality risk by EuroScore II was 1.42 ± 0.69%. The most common prosthetic sizes were 25 mm (56.6%) and 23mm (35.8%), respectively. The mortality and early re-operation rates were 5.7% and 3.8%. The mean follow-up time was 50 months. Survival rates at 3 and 5 years were 90.1% and 86.3%. Heart failure improved gradually after surgery, with NYHA class I at 3-year being 95.6%. Hemodynamic parameters (maximum, mean gradients, valve area) and left ventricular mass index were improved immediately after surgery and remained stable during follow-up. Mid-term follow-up showed no structural valve degeneration or prosthesis-related complication. Conclusion: Aortic valve replacement using a stentless bioprosthesis showed favorable mid-term outcomes, with improvement in clinical hemodynamic parameters and normalization of the left ventricular mass index. However, a longer study with a larger sample size would be required to validate the results of this study. * Keywords: Aortic valve; Aortic valve replacement using a bioprosthesis; Freedom Solo® stentless bioprosthesis.